There were twists at yesterday's Regular General Meeting of Medicon Hellas, during which the shareholders approved all items on the agenda, with the main differentiation, however, being the increase in the dividend for fiscal year 2025.
While the management's initial proposal provided for a distribution of 0.13 euros per share, after the discussion at the GM it was decided to pay a dividend of 0.15 euros per share, gross amount. The total amount of the distribution comes to 662,942.40 euros, while after the withholding of 5% tax the net amount is set at 0.1425 euros per share.
The ex-dividend date was set for Monday, July 13, 2026, beneficiaries will be the shareholders who are registered in the DSS on Tuesday, July 14, 2026, while payment will begin on Friday, July 17, 2026 through Euronext Athens and the participants in the DSS.
The matters that were approved
At the General Meeting, among other things, the annual financial statements for fiscal year 2025 were approved, the appropriation of profits, the overall management of the Board of Directors, the remuneration report, the fees of the members of the Board, and the election of an audit firm for fiscal year 2026. For the statutory audit of the financial statements, AUDITASK Certified Auditors Accountants Business Consultants S.A. was selected, with the distinctive title JPA Audit Greece.
A new seven-member Board of Directors was also elected, with a six-year term. After its constitution into a body, Spyridon Dimotsantos was appointed chairman and chief executive officer, while Georgios Dimotsantos was appointed deputy chief executive officer.
To the new Audit Committee were elected Vasileios Loumiotis, Efstratios Tserkezos and Dimitrios Kapetanakis, while a Remuneration and Nominations Committee is also being formed with members Dimitrios Kapetanakis, Efstratios Tserkezos and Spyridoula Ktisti.
The plot of land and production
Of particular interest was the management's reference to the plan for the purchase of an 8.5-stremma plot of land next to the company's facilities in Gerakas. It is a space that is currently leased and used for Medicon's logistics needs.
According to what was stated by the chairman and chief executive officer Spyridon Dimotsantos, after the completion of the agreement the company plans to transfer there the logistics that are currently housed in another of its buildings. In this way, space will be freed up for the creation of a second production unit, which will operate in support of the existing production.
The move is part of the broader plan for strengthening the company's infrastructure, at a time when Medicon seeks to further develop its presence both in diagnostics and in new categories of products and services.
The performance in 2025 and the estimates for 2026
Despite the slight decline in sales, Medicon closed 2025 with significantly improved profitability at group level. Sales, after the deduction of rebates and clawback, amounted to 17.954 million euros, from 18.375 million euros in 2024, recording a decrease of 2.29%.
However, the decline in turnover did not affect the bottom line, as EBITDA increased by 10.64%, to 3.773 million euros, while the rise in net profits was even stronger, as they increased by 32.60% and amounted to 1.769 million euros.
For 2026, according to what was said at the GM, the first half is moving close to the levels of the corresponding period last year. In diagnostics, an increase of around 2%-3% is being recorded, while the greater reduction in clawback, which in 2025 reached 12%, is estimated to be able to support profitability.
The management also referred to the company's entry into microbiology, with tests linked to antimicrobial resistance that will show to which antibiotics the patient shows resistance.
Finally, as regards the origin of revenues, exports account for approximately 20%, while the largest part of turnover comes from public hospitals. On the contrary, the participation of small private individuals currently remains limited.
The management, however, stated that Medicon intends to once again turn its attention to this specific category, seeing room for reactivation in a market where it previously had a stronger presence.